HK1201733A1 - Administration of nedd8-activating enzyme inhibitor and hypomethylating agent nedd8- - Google Patents

Administration of nedd8-activating enzyme inhibitor and hypomethylating agent nedd8-

Info

Publication number
HK1201733A1
HK1201733A1 HK15102294.2A HK15102294A HK1201733A1 HK 1201733 A1 HK1201733 A1 HK 1201733A1 HK 15102294 A HK15102294 A HK 15102294A HK 1201733 A1 HK1201733 A1 HK 1201733A1
Authority
HK
Hong Kong
Prior art keywords
nedd8
administration
enzyme inhibitor
activating enzyme
hypomethylating agent
Prior art date
Application number
HK15102294.2A
Other languages
English (en)
Chinese (zh)
Inventor
Peter G Smith
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of HK1201733A1 publication Critical patent/HK1201733A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15102294.2A 2011-11-03 2015-03-06 Administration of nedd8-activating enzyme inhibitor and hypomethylating agent nedd8- HK1201733A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161555049P 2011-11-03 2011-11-03
PCT/US2012/063382 WO2013067396A2 (en) 2011-11-03 2012-11-02 Administration of nedd8-activating enzyme inhibitor and hypomethylating agent

Publications (1)

Publication Number Publication Date
HK1201733A1 true HK1201733A1 (en) 2015-09-11

Family

ID=48193039

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102294.2A HK1201733A1 (en) 2011-11-03 2015-03-06 Administration of nedd8-activating enzyme inhibitor and hypomethylating agent nedd8-

Country Status (22)

Country Link
US (2) US8980850B2 (pt)
EP (1) EP2773360B1 (pt)
JP (2) JP6231988B2 (pt)
KR (1) KR101987861B1 (pt)
CN (1) CN104245699B (pt)
AU (1) AU2012321106C1 (pt)
BR (1) BR112014010699B1 (pt)
CA (1) CA2854461C (pt)
EA (1) EA028380B1 (pt)
ES (1) ES2668272T3 (pt)
GE (1) GEP20196940B (pt)
HK (1) HK1201733A1 (pt)
IL (1) IL232353B (pt)
MA (1) MA35662B1 (pt)
MX (1) MX357835B (pt)
MY (1) MY176125A (pt)
PL (1) PL2773360T3 (pt)
SG (1) SG11201401895WA (pt)
TN (1) TN2014000194A1 (pt)
TR (1) TR201807342T4 (pt)
UA (1) UA114414C2 (pt)
WO (1) WO2013067396A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA108986C2 (uk) 2009-05-14 2015-07-10 Мілленніум Фармасьютікалз, Інк. Кристалічна форма гідрохлориду ((1s,2s,4r)-4-{4-[(1s)-2,3-дигідро-1h-інден-1-іламіно]-7h-піроло[2,3-d]піримідин-7іл}-2-гідроксициклопентил)метилсульфамату (варіанти)
EP2748168A4 (en) * 2011-08-24 2015-04-22 Millennium Pharm Inc HEMMER OF NEDD8-ACTIVATING ENZYME
EP2764866A1 (en) * 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
US20160074404A1 (en) 2013-05-14 2016-03-17 Millennium Pharmaceutcals, Inc. Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents
US20150031643A1 (en) * 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome ii
KR102456088B1 (ko) 2014-04-04 2022-10-19 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
CN103948590A (zh) * 2014-05-22 2014-07-30 中国药科大学 Nedd8激活酶抑制剂及其医药用途
SG10201912869WA (en) * 2015-10-15 2020-02-27 Celgene Corp Combination therapy for treating malignancies
US11701406B2 (en) 2017-05-25 2023-07-18 The Board Of Trustees Of The Leland Stanford Junior University Combination of low dose IL-2 and an inhibitor of Treg IL-2R desensitization to treat autoimmune and allergic inflammatory diseases
EP3684363A4 (en) * 2017-09-21 2021-05-12 Millennium Pharmaceuticals, Inc. COCONUT CRYSTAL FORMS OF ((1S, 2S, 4R) -4- {4 - [(1S) -2,3-DIHYDRO-1H-INDEN-1-YLAMINO] -7H-PYRROLO [2,3-D] PYRIMIDINE-7- YL} -2-HYDROXYCYCLOPENTYL) -METHYL SULFAMATE, FORMULATIONS AND USES THEREOF
EP3883597A2 (en) * 2018-11-20 2021-09-29 Fulcrum Therapeutics, Inc. Compositions and methods for increasing fetal hemoglobin and treating sickle cell disease
MX2021011118A (es) 2019-03-15 2022-01-18 Fulcrum Therapeutics Inc Derivados de azolopiridina macrocíclicos como moduladores de eed y prc2.
WO2023025668A1 (en) 2021-08-25 2023-03-02 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Methods for the generation of stem cell memory t cells for adoptive t cell therapy
WO2023242235A1 (en) * 2022-06-14 2023-12-21 Scandion Oncology A/S Abcg2 inhibitor and nae inhibitor for the treatment of cancer
CN115007323B (zh) * 2022-06-17 2024-01-23 中南大学 一种抑制矿物中黄铁矿浮选的方法
WO2024012414A1 (en) * 2022-07-11 2024-01-18 Westlake University Use of a fbxo42 specific inhibitor in treating notch signaling-dependent disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
WO2006084281A1 (en) 2005-02-04 2006-08-10 Millennium Pharmaceuticals, Inc. Inhibitors of e1 activating enzymes
WO2007092213A2 (en) 2006-02-02 2007-08-16 Millennium Pharmaceuticals, Inc. Inhibitors of e1 activating enzyme
RS51549B (en) * 2006-08-08 2011-06-30 Millennium Pharmaceuticals Inc. HETEROARIL UNITS USEFUL AS INVESTIGATIVE ENZYME E1 INHIBITORS
WO2008028193A2 (en) 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
WO2009058394A1 (en) 2007-11-01 2009-05-07 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
EP2257310A2 (en) * 2008-02-26 2010-12-08 Nerviano Medical Sciences S.r.l. Antitumor combination comprising a morpholinyl anthracycline derivative and demethylating agents
DK3782612T3 (da) 2008-05-15 2024-01-15 Celgene Corp Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
JP6006938B2 (ja) * 2008-06-09 2016-10-12 サイクラセル リミテッド スパシタビン(cndac)と、デシタビン及びプロカイン等のdnaメチルトランスフェラーゼ阻害剤との組合せ
AU2010228982B2 (en) * 2009-03-23 2015-05-14 Ambit Biosciences Corporation Methods of treatment using combination therapy
UA108986C2 (uk) 2009-05-14 2015-07-10 Мілленніум Фармасьютікалз, Інк. Кристалічна форма гідрохлориду ((1s,2s,4r)-4-{4-[(1s)-2,3-дигідро-1h-інден-1-іламіно]-7h-піроло[2,3-d]піримідин-7іл}-2-гідроксициклопентил)метилсульфамату (варіанти)
WO2012106299A1 (en) 2011-01-31 2012-08-09 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
BR112014010417A2 (pt) 2011-11-01 2014-11-18 Celgene Corp Métodos para o tratamento de cânceres com o uso de formulações orais de análogos de citidina

Also Published As

Publication number Publication date
IL232353A0 (en) 2014-06-30
AU2012321106A1 (en) 2013-05-23
UA114414C2 (uk) 2017-06-12
GEP20196940B (en) 2019-01-10
JP2015505816A (ja) 2015-02-26
WO2013067396A2 (en) 2013-05-10
TN2014000194A1 (en) 2015-09-30
KR101987861B1 (ko) 2019-06-11
EP2773360A4 (en) 2015-09-23
MY176125A (en) 2020-07-24
BR112014010699B1 (pt) 2020-12-15
CN104245699B (zh) 2017-06-27
JP6231988B2 (ja) 2017-11-15
EA028380B1 (ru) 2017-11-30
MX357835B (es) 2018-07-26
US20130116208A1 (en) 2013-05-09
BR112014010699A2 (pt) 2017-04-25
CA2854461A1 (en) 2013-05-10
US20150366886A1 (en) 2015-12-24
NZ624881A (en) 2016-10-28
CN104245699A (zh) 2014-12-24
MX2014005323A (es) 2014-06-05
KR20140097229A (ko) 2014-08-06
US8980850B2 (en) 2015-03-17
AU2012321106C1 (en) 2016-11-24
JP2018009035A (ja) 2018-01-18
CA2854461C (en) 2021-01-19
TR201807342T4 (tr) 2018-06-21
PL2773360T3 (pl) 2018-09-28
IL232353B (en) 2018-11-29
WO2013067396A3 (en) 2014-10-16
EA201400539A1 (ru) 2014-12-30
EP2773360B1 (en) 2018-02-28
MA35662B1 (fr) 2014-11-01
AU2012321106B2 (en) 2016-08-04
SG11201401895WA (en) 2014-05-29
ES2668272T3 (es) 2018-05-17
EP2773360A2 (en) 2014-09-10

Similar Documents

Publication Publication Date Title
HK1201733A1 (en) Administration of nedd8-activating enzyme inhibitor and hypomethylating agent nedd8-
HRP20180953T1 (hr) Supstituirani 3-haloalilaminski inhibitori za ssao i njihove uporabe
HK1246674A1 (zh) 犬尿氨酸-3-單加氧酶抑制劑、藥物組合物及其使用方法
HK1199726A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
HK1203853A1 (en) Inhibitors of arginase and their therapeutic applications
EP2678018A4 (en) COMBINATION OF CHINESE HEMMER AND USES THEREOF
HK1202112A1 (en) Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
HK1202244A1 (en) Prebiotic formulations and methods of use
EP2721019A4 (en) THERAPEUTIC ACTIVE COMPOSITIONS AND METHOD FOR THEIR USE
HK1198619A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
EP2790709A4 (en) HEMOSTATIC ACTIVE SUBSTANCES AND METHOD OF USE THEREOF
IL232115A0 (en) Pharmaceutical preparations that include dgla and/or 15-hetre and methods of using them
EP2635287A4 (en) NEDD8 ACTIVATOR ENZYME INHIBITOR ADMINISTRATION
HK1201066A1 (en) Pyranopyridone inhibitors of tankyrase
EP2688901A4 (en) INHIBITORS OF 17SS-HSD1, 17SS-HSD3 AND 17SS-HSD10